Biomaterial Database

Effects of low-dose 17-beta-estradiol plus norethisterone acetate and tibolone on fasting plasma homocysteine levels in postmenopausal women. 2003

Babur Kaleli, and Basak Yildirim, and Suleyman Demir, and Erkan Alatas

Departments of Obstetrics and Gynecology and Biochemistry, Medical Faculty, Pamukkale University, Denizli, Turkey. bkaleli@netscape.net

BACKGROUND Many postmenopausal women currently receive hormone replacement therapy. The use of low-dose 17beta-estradiol plus norethisterone acetate and tibolone for hormone replacement therapy is not uncommon in postmenopausal women. Homocysteine, which is known to be an independent risk factor for the development of cardiovascular disease, is found in increased levels postmenopause. This study compared the effects of low-dose 17beta-estradiol plus norethisterone acetate and tibolone on the fasting plasma homocysteine level in healthy postmenopausal women. METHODS Healthy postmenopausal women (n = 44) were enrolled in the study. Women randomly assigned received 1 mg of 17beta-estradiol plus 0.5 mg of norethisterone acetate or 2.5 mg tibolone during a period of 12 weeks. Fasting plasma homocysteine levels were measured at baseline, the 4th week, and the 12th week of therapy. RESULTS In the 4th week there were no significant changes in plasma homocysteine levels in both groups (p > 0.05). However at the end of the 12th week the plasma homocysteine levels were reduced significantly in both groups (p < 0.05). CONCLUSIONS Low-dose 17beta-estradiol plus norethisterone acetate and tibolone lower the fasting plasma homocysteine levels in healthy postmenopausal women.

UI	MeSH Term	Description	Entries
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D009640	Norethindrone	A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION.	19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17alpha)-,Ethinylnortestosterone,Norethisterone,Norpregneninolone,Conceplan,Micronor,Monogest,Nor-QD,Norcolut,Norcolute,Norethindrone, (1 beta)-Isomer,Norlutin,Nor QD,NorQD
D009652	Norpregnenes	Pregnenes with one double bond or more than three double bonds which have undergone ring contractions or are lacking carbon-18 or carbon-19..
D011336	Probability	The study of chance processes or the relative frequency characterizing a chance process.	Probabilities
D012016	Reference Values	The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality.	Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D004305	Dose-Response Relationship, Drug	The relationship between the dose of an administered drug and the response of the organism to the drug.	Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334	Drug Administration Schedule	Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.	Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359	Drug Therapy, Combination	Therapy with two or more separate preparations given for a combined effect.	Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004958	Estradiol	The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.	17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005215	Fasting	Abstaining from FOOD.	Hunger Strike,Hunger Strikes,Strike, Hunger,Strikes, Hunger

Related Publications

Babur Kaleli, and Basak Yildirim, and Suleyman Demir, and Erkan Alatas

Clinical effects of 17 beta-estradiol and norethisterone acetate in postmenopausal Thai women.

April 2000, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,

Babur Kaleli, and Basak Yildirim, and Suleyman Demir, and Erkan Alatas

Tibolone and estradiol plus norethisterone acetate similarly influence endothelium-dependent vasodilatation in healthy postmenopausal women.

August 2006, Fertility and sterility,

Babur Kaleli, and Basak Yildirim, and Suleyman Demir, and Erkan Alatas

Effects of tibolone on plasma homocysteine levels in postmenopausal women.

August 2002, Fertility and sterility,

Babur Kaleli, and Basak Yildirim, and Suleyman Demir, and Erkan Alatas

Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women.

February 2008, Climacteric : the journal of the International Menopause Society,

Babur Kaleli, and Basak Yildirim, and Suleyman Demir, and Erkan Alatas

Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels.

December 2000, Fertility and sterility,

Babur Kaleli, and Basak Yildirim, and Suleyman Demir, and Erkan Alatas

A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women.

January 2000, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,

Babur Kaleli, and Basak Yildirim, and Suleyman Demir, and Erkan Alatas

Effects of low- or high-dose hormone therapy on fasting and post-methionine homocysteine levels in postmenopausal women.

October 2006, Climacteric : the journal of the International Menopause Society,

Babur Kaleli, and Basak Yildirim, and Suleyman Demir, and Erkan Alatas

Treatment of climacteric and postmenopausal women with 17-beta-oestradiol and norethisterone acetate.

January 1977, Acta obstetricia et gynecologica Scandinavica,

Babur Kaleli, and Basak Yildirim, and Suleyman Demir, and Erkan Alatas

Pharmacokinetic studies on low dose estradiol 17 beta administered orally to postmenopausal women.

January 1980, Acta obstetricia et gynecologica Scandinavica,

Babur Kaleli, and Basak Yildirim, and Suleyman Demir, and Erkan Alatas

A comparison of effects of sequential transdermal administration versus oral administration of estradiol plus norethisterone acetate on serum NO levels in postmenopausal women.

January 2006, Maturitas,